Page 24 - TD-2-2

Tumor Discovery Practice and consideration of master protocol design

11. Janiaud P, Serghiou S, Ioannidis JPA, 2019, New clinical 26. Wang H, Yee D, 2019, I-SPY 2: A neoadjuvant adaptive
trial designs in the era of precision medicine: An overview clinical trial designed to improve outcomes in high-risk
of definitions, strengths, weaknesses, and current use in breast cancer. Curr Breast Cancer Rep, 11(4): 303–310.
oncology. Cancer Treat Rev, 73: 20–30. 27. Chen AP, Kummar S, Moore N, et al., 2021, Molecular
12. Bitterman DS, Cagney DN, Singer LL, et al., 2020, Master profiling-based assignment of cancer therapy
protocol trial design for efficient and rational evaluation (NCI-MPACT): A randomized multicenter phase II trial.
of novel therapeutic oncology devices. J Natl Cancer Inst, JCO Precis Oncol, 5: 133–144.
112(3): 229–237. 28. Kim ES, Herbst RS, Wistuba II, et al., 2011, The BATTLE
13. Couwenberg A, van der Heide U, Janssen T, et al., 2022, trial: Personalizing therapy for lung cancer. Cancer Discov,
Master protocol trial design for technical feasibility of 1(1): 44–53.
MR-guided radiotherapy. Radiother Oncol, 166: 33–36. 29. Le Tourneau C, Delord JP, Gonçalves A, et al., 2015,
14. Chetty IJ, Martel MK, Jaffray DA, et al., 2015, Technology Molecularly targeted therapy based on tumour molecular
for innovation in radiation oncology. Int J Radiat Oncol Biol profiling versus conventional therapy for advanced cancer
Phys, 93(3): 485–492. (SHIVA): A multicentre, open-label, proof-of-concept,
randomised, controlled phase 2 trial. Lancet Oncol,
15. Kavanagh B, 2019, Radiation oncology APM: Why us? Why 16(13): 1324–1334.
now? Int J Radiat Oncol Biol Phys, 105(1): 22–24.
30. Kunkler IH, Ward C, Langdon SP, 2015, Technical
16. Hu C, Dignam JJ, 2019, Biomarker-driven oncology clinical innovation in adjuvant radiotherapy: Evolution and
trials: Key design elements, types, features, and practical evaluation of new treatments for today and tomorrow.
considerations. JCO Precis Oncol, 1: 1-12. Breast, 24(Suppl 2): S114–S119.
17. Saville BR, Berry SM, 2016, Efficiencies of platform clinical 31. Stereotactic Magnetic Resonance Guided Radiation
trials: A vision of the future. Clin Trials, 13(3): 358–366. Therapy. Available from: https://clinicaltrials.gov/ct2/show/
18. Berry SM, Connor JT, Lewis RJ, 2015, The platform trial: An nct04115254?term=nct04115254&draw=2&rank=1 [Last
efficient strategy for evaluating multiple treatments. JAMA, accessed on 2023 Apr 26].
313(16): 1619–1620. 32. Lih CJ, Takebe N, 2017, Considerations of developing an
19. Collignon O, Gartner C, Haidich AB, et al., 2020, Current NGS assay for clinical applications in precision oncology:
statistical considerations and regulatory perspectives on the The NCI-MATCH NGS assay experience. Curr Probl
planning of confirmatory basket, umbrella, and platform Cancer, 41(3): 201–211.
trials. Clin Pharmacol Ther, 107(5): 1059–1067. 33. Systemic Therapy with or without Local Consolidative
20. Heinrich MC, Joensuu H, Demetri GD, et al., 2008, Therapy in Treating Patients with Oligometastatic Solid
Phase II, open-label study evaluating the activity of imatinib Tumor. Available from: https://clinicaltrials.gov/ct2/show/
in treating life-threatening malignancies known to be nct03599765?term=nct03599765&draw=2&rank=1 [Last
associated with imatinib-sensitive tyrosine kinases. Clin accessed on 2023 Apr 26].
Cancer Res, 14(9): 2717–2725. 34. Ow TJ, Mehta V, Gersten AJ, et al., 2022, A phase 0 master
21. Moro-Sibilot D, Cozic N, Pérol M, et al., 2019, Crizotinib in protocol utilizing a novel intratumoral microdosing
c-MET-or ROS1-positive NSCLC: Results of the AcSé phase approach for simultaneously evaluating multiple drugs
II trial. Ann Oncol, 30(12): 1985–1991. and drug combinations in patients with solid tumors. Int J
Radiat Oncol Biol Phys, 112(5): e48.
22. Murciano-Goroff YR, Drilon A, Stadler ZK, 2021, The NCI-
MATCH: A national, collaborative precision oncology trial 35. Welsh JW, Tang C, de Groot P, et al., 2019, Phase II trial
for diverse tumor histologies. Cancer Cell, 39(1): 22–24. of ipilimumab with stereotactic radiation therapy for
metastatic disease: Outcomes, toxicities, and low-dose
23. Redman MW, Papadimitrakopoulou VA, Minichiello K, radiation-related abscopal responses. Cancer Immunol Res,
et al., 2020, Biomarker-driven therapies for previously 7(12): 1903–1909.
treated squamous non-small-cell lung cancer (Lung-MAP
SWOG S1400): A biomarker-driven master protocol. Lancet 36. Atezolizumab Combined with BDB001 and Immunogenic
Oncol, 21(12): 1589–1601. Radiotherapy in Patients with Advanced Solid Tumors
(AGADIR). Available from: https://clinicaltrials.gov/ct2/
24. Gerber DE, Oxnard GR, Govindan R, 2015, ALCHEMIST: show/nct03915678?term=nct03915678&draw=2&rank=1
Bringing genomic discovery and targeted therapies to early- [Last accessed on 2023 Apr 26].
stage lung cancer. Clin Pharmacol Ther, 97(5): 447–450.
37. Jump: MR Simulation For Radiation Therapy Master Protocol
25. Schmoll HJ, 2018, FOCUS4: A new trial design for evaluation (JUMP). Available from: https://clinicaltrials.gov/ct2/show/
of targeted drugs in colorectal cancer? Lancet Gastroenterol nct04545957?term=nct04545957&draw=2&rank=1 [Last
Hepatol, 3(3): 143–145. accessed on 2023 Apr 26].

Volume 2 Issue 2 (2023) 18 https://doi.org/10.36922/td.342